HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Clinical trial NCT06364007 · UNKNOWN

Trial details

NCT number: NCT06364007
Sponsor: Sulai Liu
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-03-03
Primary completion: 2025-12-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.